Search

Without access to treatment, can we truly innovate in rare diseases?

Interview with Giampaolo Merlini

There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.

Read more

Young EHA Committee

Welcome to the family! Get to know the Young EHA Committee and learn how you can make a difference. Join Young EHA through a junior membership.

Read more

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

 

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

Read more

Highlights of the EHA-EMA Joint Symposium on RWE

The fourth EHA-EMA Joint Symposium at EHA2024 brought together investigators, regulators and patients to discuss the use of real world evidence (RWE) in the evaluation of new drugs.

Read more

Evidence and policy to ensure good clinical practice

Interview with Vinay Prasad MD MPH by Heiko Becker MD, on behalf of YoungEHA

Leaders in the field that have the potential to make a difference, that challenge the way we are doing things, who push our perspective out of our…

Read more

Special train fare discount

Discounts of up to 75% on Trenitalia train journeys for EHA2025 delegates.

Read more

5th Focus in Paediatric Haematology-Oncology

The course, which is particularly aimed at specialist trainees in pediatric haemato-oncology, continued the same ethos which inspired the first four courses: the importance of close interactions between the participants and the teaching faculty, a strong emphasis on real cases…

Read more